This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Walgreen Investors Focus on Buybacks with Inversion Now Dead

NEW YORK (TheStreet) – Walgreen (WAG) is being pressed by investors to increase its share buyback activity, sources close to the situation told TheStreet, with some analysts stating the company could buy back up to 130 million shares through a leveraged recapitalization of its balance sheet.

These shareholder complaints stem from Walgreen's guidance for the second leg of its acquisition of Alliance Boots, which stipulated that the pharmacy giant will keep its headquarters in the Chicago area, shake up its board and executive ranks, and buy back up to $3 billion worth of stock by 2016. Large investors, some of whom had initiated calls for Walgreens to consider shifting its headquarters abroad as part of its Alliance Boots acquisition, continue to focus on changing the company's capital structure as the Alliance Boots deal moves to completion, the sources said.

Barclays Capital analyst Meredith Adler characterized Walgreen's buyback plans as a "disservice to shareholders" on an Aug. 6 conference call and said the company could buy back $3 billion in stock this year. In June, Adler said in a report Walgreens could spend north of $14 billion on a leveraged recapitalization of its balance sheet so long as it also provided a debt reduction plan to bond rating agencies.

While Walgreen's financial outlook soured in August, the company's capital structure and share buyback activity remains an area where investors may have the biggest influence now that the inversion debate is dead.

Read More: Walgreens Never Said it would Do an Inversion

Despite speculation of a potential inversion, the company never actually said it would make such a move. Meanwhile, vocal investors weren't just calling for a tax move abroad; they also lobbied to have Alliance Boots management take a substantial role within the combined company, and for Walgreens to improve its capital allocation policy.

Walgreens appears to have generally met investor demands by putting key Alliance Boots executives such as CEO Stefano Pessina, Alex Gourlay and Ornella Barra in top roles within the combined company, now called Walgreens Boots Alliance. But, Walgreens disappointed investors and also the analyst community when it came to earnings guidance and the company's thinking on capital structure.

Investors believe Walgreens has the ability to use cash on its balance sheet and new debt to meaningfully increase its share buyback activity, even as it works to close the Alliance Boots transaction and refinance higher-cost debts.

Currently, Walgreens operates at a debt level of just one times earnings before interest, taxes, depreciation and amortization (EBITDA). While Walgreens is forecast to take on roughly $8.5 billion in debt with Alliance Boots, a formerly KKR-owned company, it is forecast by Deutsche Bank analysts to have debt of just 1.9 times EBITDA by fiscal 2015 and 1.4 times EBITDA by 2016. Investors have long looked at those low debt levels, in addition to balance sheet cash as a missed opportunity to create value.

However, Walgreens left its capital structure and buyback activity largely intact on Aug. 6 when announcing the second phase of its Alliance Boots purchase. The company said it will buy back $3 billion in stock through 2016. Investors and analysts think Walgreen's is capable of a leveraged recapitalization and those total buybacks annually.

A difference of opinion on the importance of maintaining current bond ratings appears to be driving a wedge between Walgreens and its investors.

Walgreens said on Aug. 6 its stock buyback plans hinge on maintaining investment grade credit ratings. Treasurer Jason Dubinsky said Walgreens did not want top drop below mid-BBB ratings at both Standard & Poor's and Moody's, citing the company's emphasis on financial flexibility and continued access to commercial paper markets.

"[W]e've adequately sized the share repurchase capacity to keep us in that zone, and we're confident that that's the right place to be for us right now and for the longer term," Dubinsky concluded. To Dubinsky's point, Moody's Investor Service placed Walgreen's Baa1 rating on review for a downgrade on Aug. 6, citing the company's buyback plan.

Investors, however, disagree with Walgreens and they have voiced their concerns to the company.

"Subsequent to our investor call on Aug. 6, we have received feedback from several shareholders regarding our overall capital allocation policy that we set forth on the call," Walgreens spokesperson Michael Polzin said in an e-mail to TheStreet.

"We are always open and receptive to shareholders' views, and we will accordingly ensure that our board has received this feedback and will keep it in mind as it considers future activity," Polzin added, while declining to name the investors who had spoken to Walgreen's or to elaborate on their demands.

Jana Partners, one of Walgreen's most vocal hedge funds shareholders, will remain a large investor in the company and continue to express its views on capital allocation to management, a source with knowledge of the fund's thinking told TheStreet. Jana Partners, in addition to other shareholders such as Och-Ziff Management, Viking Global Management and Corvex Management, declined to comment for this article.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
WAG $81.65 2.05%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs